BG105932A - Methods and compositions using (-)norcisapride in combination with proton pump inhibitors or h2 receptor antagonists - Google Patents

Methods and compositions using (-)norcisapride in combination with proton pump inhibitors or h2 receptor antagonists

Info

Publication number
BG105932A
BG105932A BG105932A BG10593201A BG105932A BG 105932 A BG105932 A BG 105932A BG 105932 A BG105932 A BG 105932A BG 10593201 A BG10593201 A BG 10593201A BG 105932 A BG105932 A BG 105932A
Authority
BG
Bulgaria
Prior art keywords
compositions
methods
norcisapride
combination
receptor antagonists
Prior art date
Application number
BG105932A
Other languages
Bulgarian (bg)
English (en)
Inventor
Paul Rubin
Timothy Barberich
Original Assignee
Sepracor, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor, Inc filed Critical Sepracor, Inc
Publication of BG105932A publication Critical patent/BG105932A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG105932A 1999-03-02 2001-09-21 Methods and compositions using (-)norcisapride in combination with proton pump inhibitors or h2 receptor antagonists BG105932A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12239399P 1999-03-02 1999-03-02
PCT/US2000/005167 WO2000051584A2 (fr) 1999-03-02 2000-03-01 Procedes et compositions destines a l'utilisation de norcisapride (-) en combinaison avec des inhibiteurs de pompes a protons ou des antagonistes du recepteur de h¿2?

Publications (1)

Publication Number Publication Date
BG105932A true BG105932A (en) 2002-12-29

Family

ID=22402453

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105932A BG105932A (en) 1999-03-02 2001-09-21 Methods and compositions using (-)norcisapride in combination with proton pump inhibitors or h2 receptor antagonists

Country Status (21)

Country Link
US (2) US6362202B1 (fr)
EP (1) EP1156853A2 (fr)
JP (1) JP2002538104A (fr)
KR (1) KR20010108299A (fr)
CN (1) CN1399572A (fr)
AR (1) AR022811A1 (fr)
AU (1) AU3710800A (fr)
BG (1) BG105932A (fr)
BR (1) BR0008664A (fr)
CA (1) CA2362488A1 (fr)
CO (1) CO5150222A1 (fr)
EA (1) EA200100937A1 (fr)
EE (1) EE200100459A (fr)
HU (1) HUP0200151A3 (fr)
IL (1) IL145163A0 (fr)
NO (1) NO20014229L (fr)
NZ (1) NZ513967A (fr)
PL (1) PL350862A1 (fr)
SK (1) SK12342001A3 (fr)
TR (1) TR200103128T2 (fr)
WO (1) WO2000051584A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6821285B2 (en) 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
US6663639B1 (en) * 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US7846180B2 (en) 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
US8287554B2 (en) * 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
WO2002041918A2 (fr) * 2000-11-24 2002-05-30 Janssen Pharmaceutica N.V. Utilisation d'une combinaison triple contenant un antagoniste 5ht3, un agoniste 5ht4 et un laxatif facilitant le lavement intestinal
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
AU2002365936A1 (en) * 2001-11-16 2003-09-02 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
AU2002366796A1 (en) * 2001-12-19 2003-07-09 Eisai Co. Ltd Methods using proton pump inhibitors
AU2003241464A1 (en) * 2002-05-17 2003-12-02 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
WO2004024192A1 (fr) * 2002-09-12 2004-03-25 University Of Chicago Controle et diagnostic de vidage gastrique et de gastroparesie
FR2845916B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
SE0203410D0 (sv) * 2002-11-18 2002-11-18 Astrazeneca Ab New use
KR20050094843A (ko) * 2003-01-13 2005-09-28 다이노젠 파마세우티컬스, 인코포레이티드 욕지기, 구토, 구역질 또는 이들의 조합을 치료하는 방법
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
US20040192781A1 (en) * 2003-03-31 2004-09-30 Haley Eugene T. Method of administration for metoclopramide and pharmaceutical formulation therefor
WO2004089414A2 (fr) * 2003-04-08 2004-10-21 Medley S.A. Indústria Farmacêutica Combinaison de medicaments, association de medicaments et medicament
JP2007507425A (ja) * 2003-08-29 2007-03-29 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 胃腸管運動障害を処置するために有用な組成物
WO2006011159A2 (fr) * 2004-06-21 2006-02-02 Torrent Pharmaceuticals Limited Composition pharmaceutique stabilisee contenant du sodium de rabeprazole presentant une biodisponibilite amelioree
US20060046998A1 (en) * 2004-08-25 2006-03-02 Fairfield Clinical Trials, Llc Method of treatment of gastroesophageal reflux disease and laryngopharyngeal reflux disease
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7730891B2 (en) * 2005-10-07 2010-06-08 Lamberg Steven B Intraoral mandibular advancement device for treatment of sleep disorders
US20070079833A1 (en) * 2005-10-07 2007-04-12 Lamberg Steven B Intraoral mandibular advancement device for treatment of sleep disorders, including snoring, obstructive sleep apnea, and gastroesophageal reflux disease and method for delivering the same
GB0606426D0 (en) * 2006-03-30 2006-05-10 Novartis Ag Benzimidazole derivatives
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
US20080234703A1 (en) * 2007-03-23 2008-09-25 Ethicon Endo-Surgery, Inc. Tissue approximation system
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5914460B2 (ja) 1978-12-27 1984-04-04 相互薬工株式会社 Ｈ↓２受容体「きつ」抗剤シメチジンの製造法
CA1183847A (fr) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide; derives
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
SE8204879D0 (sv) 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
US4598123A (en) 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
SI8710091A8 (en) 1987-01-23 1996-06-30 Lek Tovarna Farmacevtskih Process for obtaining crystalline cimetadine (n-cyano-n'-methyl-n"- (2/(5-methyl-1h-imidazole-4-yl)methylthio/ethyl)-guanidine
IT1215344B (it) 1987-01-27 1990-02-08 Dessy S R L Ora Recordati Farm Procedimento per la preparazione di composti ad attivita' anti-ulcera.
JPH0623181B2 (ja) 1987-02-17 1994-03-30 三井石油化学工業株式会社 シアノグアニジン誘導体及びその製造法
JPH0623180B2 (ja) 1987-02-17 1994-03-30 三井石油化学工業株式会社 シアノグアニジン誘導体及びその製造法
US4800162A (en) 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
SE9002043D0 (sv) 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
DK0617620T3 (da) 1991-12-21 1999-06-07 Smithkline Beecham Plc Anvendelse af 5-HT4-modulatorer til fremstilling af et lægemiddel til behandling af blærelidelser
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA2139638A1 (fr) 1992-07-07 1994-01-20 Nancy M. Gray Methodes d'utilisation de la (-) cisapride pour le traitement du reflux gastro-oesophagien et d'autres troubles
CA2139636A1 (fr) 1992-07-07 1994-01-20 Nancy M. Gray Methodes d'utilisation de la (+) cisapride pour le traitement du reflux gastro-oesophagien et d'autres troubles
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
EP0707492A1 (fr) 1993-07-06 1996-04-24 Merck & Co. Inc. Combinaisons d'agents anti-h 2? et d'agents de motilite gastro-intestinale
US5502195A (en) 1993-11-04 1996-03-26 Slemon; Clarke Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole
US5374730A (en) 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5541335A (en) 1994-07-11 1996-07-30 Torcan Chemical Ltd. Process for preparing nizatidine
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735475B1 (fr) 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
CN1196681C (zh) * 1997-07-11 2005-04-13 詹森药业有限公司 (+)诺西沙必利用于制备5－ht3和5ht4 介导的疾病的药物中的用途
SK19062000A3 (sk) * 1998-06-15 2001-07-10 Sepracor, Inc. Použitie (-)-norcisapridu alebo jeho farmaceuticky prijateľnej soli, v podstate bez jeho (+) stereoizoméru, na liečenie apnoe, bulímie a iných porúch
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists

Also Published As

Publication number Publication date
NO20014229D0 (no) 2001-08-31
WO2000051584A3 (fr) 2001-09-07
AR022811A1 (es) 2002-09-04
EA200100937A1 (ru) 2002-10-31
AU3710800A (en) 2000-09-21
EE200100459A (et) 2002-12-16
EP1156853A2 (fr) 2001-11-28
US6362202B1 (en) 2002-03-26
NZ513967A (en) 2001-09-28
IL145163A0 (en) 2002-06-30
SK12342001A3 (sk) 2002-01-07
CO5150222A1 (es) 2002-04-29
CN1399572A (zh) 2003-02-26
WO2000051584A2 (fr) 2000-09-08
KR20010108299A (ko) 2001-12-07
NO20014229L (no) 2001-11-01
HUP0200151A3 (en) 2003-09-29
PL350862A1 (en) 2003-02-10
BR0008664A (pt) 2001-12-18
JP2002538104A (ja) 2002-11-12
HUP0200151A2 (en) 2002-06-29
CA2362488A1 (fr) 2000-09-08
US6548518B2 (en) 2003-04-15
TR200103128T2 (tr) 2002-03-21
US20020086881A1 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
BG105932A (en) Methods and compositions using (-)norcisapride in combination with proton pump inhibitors or h2 receptor antagonists
BG105933A (en) Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
CA2359363A1 (fr) 4-(heterocyclysulfonamido)-5-methoxy-6-(2-methoxyphenoxy)-2-phenyle ou pyridylpyrimidines faisant office d'antagonistes des recepteurs de l'endotheline
RS51672B (en) FLUOROSubstituted Cycloalkanoindoles and Their Use as Prostaglandin D2 Receptor Antagonists
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
SG146657A1 (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
MXPA05002442A (es) Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
DK1176963T3 (da) Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser
DK1129091T3 (da) Antagonister for CRF-receptorer og fremgangsmåder med relation dertil
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
MY127120A (en) A1 adenosine receptor antagonists
DK1079843T3 (da) Anvendelse af a1beta1 integrinreceptorinhibitorer og TFG beta1 inhibitorer til behandling af nyresygdom
BG105097A (en) Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
HK1046143A1 (en) Substituted benzimidazole, the production thereof and the use thereof as means against parasitic protozoa
MXPA02012574A (es) Uso novedoso de los antagonistas ii de angiotensina.
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
MXPA04011018A (es) Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
SE0300988D0 (sv) New use
RS95204A (en) Combination for the treatment of airway disorders
BR0314388A (pt) Combinações de atorvastatina e antagonistas de receptores adrenérgicos alfa1